

Please amend the application as follows:

In the Claims:

- Sub
GI
- 1 1. (Twice Amended) A polypeptide comprising an amino acid sequence from Ala at
 - 2 position 14 to Gly at position 226 of SEQ ID NO:2 and having the biological property
 - 3 of gankyrin, wherein said polypeptide does not contain a signal sequence.

Same as 265 polypeptide compound in Kato et al

REMARKS

Applicant respectfully requests reconsideration of the present application in view of the foregoing amendments and in view of the response to Office Action filed March 13, 2002. The supplemental amendment to claim 1, filed herewith, is fully supported by the specification. The amendment to claim 1 is intended to better capture the commercial embodiment of the claimed invention.

The Examiner is invited to contact the undersigned by telephone if it is felt that a telephone interview would advance the prosecution of the present application.

Respectfully submitted,

Date

March 22, 2002

FOLEY & LARDNER
Washington Harbour
3000 K Street, N.W., Suite 500
Washington, D.C. 20007-5143
Telephone: (202) 672-5571
Facsimile: (202) 672-5399

By

For [Signature] 48,574

Harold C. Wegner
Attorney for Applicant
Registration No. 25,258

VERSION WITH MARKINGS TO SHOW CHANGES MADE UNDER 37 C.F.R. § 1.121(c)(ii)

1. A polypeptide comprising [consisting of] an amino acid sequence from Ala at position 14 to Gly at position 226 of SEQ ID NO: 2 and having the biological activity of gankyrin, wherein said polypeptide does not contain a signal sequence.